Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-06-14
2011-06-14
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C530S388220, C562S496000
Reexamination Certificate
active
07959918
ABSTRACT:
Compositions and methods included herein describe the treatment of atherosclerosis and other vascular diseases such as thrombosis, restenosis after angioplasty and/or stenting, and vein-graft disease after bypass surgery, by inhibition of the expression or biologic activity of the toll-like receptor 4 (TLR4) and/or myeloid differentiation factor 88 (MyD88). TLR4 cell signal transduction is at least partially responsible for the manifestation, continuation, and/or worsening of atherosclerosis and other forms of vascular disease. The present invention provides several means with which to inhibit this signal transduction pathway by affecting the biological activity of the TLR4 receptor and/or MyD88.
REFERENCES:
patent: 6323334 (2001-11-01), Kingsbury et al.
patent: 7312320 (2007-12-01), Elson
patent: 2003/0077279 (2003-04-01), Arditi et al.
patent: 2003/0148986 (2003-08-01), Arditi et al.
patent: 2003/0232352 (2003-12-01), Schwartz et al.
patent: 03/050137 (2003-06-01), None
patent: 2004/031225 (2004-04-01), None
patent: 2004/093778 (2004-11-01), None
Bjorbacka H., et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nature Medicine, 2004, vol. 10, No. 4, p. 416-421.
Bartfai T., et al. A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc. Natl. Acad. Sci. USA, 2003, vol. 100, No. 13, p. 7971-7976.
Burns K., et al. MyD88, an adapter protein involved in interleukin-1 signaling. J. Biol. Chem. 1998, vol. 273, No. 20, p. 12203-12209.
Pasterkamp, et al. “Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease”, European Journal of Clinal Investigation (2004) 34, 328-334.
Fort M.M, et al. “A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease”, J. Immumnolgy, 2005, vol. 174, p. 6416-6423.
Van Tassell B.W., et al. “Pharmacological inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse”, J. Cardiovascular Pharmacology, 2010, vol. 55, p. 385-390.
Gupta B, et al. “Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides”, Advanced Drug Delivery Reviews, 2005, vol. 57, p. 637-651.
Fitzgerald K.A., et al. “Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction”, Nature, 2001, vol. 413, p. 78-83.
Ronni T, et al. “Common interaction surfaces of the toll-like receptor 4 cytoplasmic domain stimulate multiple nuclear targets”, Molecular and Cellular Biology, 2003, vol. 23, p. 2543-2555.
Burns, K. et al., MyD88, an Adapter Protein Involved in Interleukin-1 Signaling, Journal of Biological Chemistry, May 15, 1998, 273:20, pp. 12203-12209.
Ulevitch, R.J. et al., Therapeutics Targeting the Innate Immune System, Immunology, Jul. 1, 2004, 4:7, pp. 512-520.
Zuan-Amorim, C. et al., Toll-Like Receptors as Potential Therapeutic Targets for Multiple Diseases, Nature Reviews/Drug Discovery, Oct. 2002, pp. 797-807.
International Search Report and Written Opinion, PCT/US09/50317; Dec. 10, 2009.
Kim, et al. “Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist eritoran,” Cell, vol. 130, Sep. 7, 2007; 906-907.
Ohta, et al. “Identification of a novel isoform of MD-2 that downregulates lipopolysaccharide signaling,” Biochemical and Biophysical Research Communications, vol. 323 (2004); 1103-1108.
Shimazu, et al. “MD-2, a molecule that confers lipopolysaccharide responsiveness on toll-like receptor 4,” Journal of Experimental Medicine, vol. 189, No. 11, Jun. 7, 1999; 1777-1782.
Arditi Moshe
Rajavashisth Tripathi
Shah Prediman K.
Cedars-Sinai Medical Center
Davis , Wright, Tremaine, LLP
Hissong Bruce D
Landsman Robert
Levy Seth D.
LandOfFree
Methods for treating vascular disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating vascular disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating vascular disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2681124